MX2022015254A - N-cianopirrolidinas con actividad como inhibidores de peptidasa especifica de ubiquitina 30. - Google Patents

N-cianopirrolidinas con actividad como inhibidores de peptidasa especifica de ubiquitina 30.

Info

Publication number
MX2022015254A
MX2022015254A MX2022015254A MX2022015254A MX2022015254A MX 2022015254 A MX2022015254 A MX 2022015254A MX 2022015254 A MX2022015254 A MX 2022015254A MX 2022015254 A MX2022015254 A MX 2022015254A MX 2022015254 A MX2022015254 A MX 2022015254A
Authority
MX
Mexico
Prior art keywords
cyanopyrrolidines
activity
ubiquitin
specific peptidase
peptidase inhibitors
Prior art date
Application number
MX2022015254A
Other languages
English (en)
Inventor
Mark Ian Kemp
Paul William Thompson
Christopher Andrew Luckhurst
Original Assignee
Mission Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2008401.8A external-priority patent/GB202008401D0/en
Priority claimed from GBGB2016689.8A external-priority patent/GB202016689D0/en
Priority claimed from GBGB2101935.1A external-priority patent/GB202101935D0/en
Application filed by Mission Therapeutics Ltd filed Critical Mission Therapeutics Ltd
Publication of MX2022015254A publication Critical patent/MX2022015254A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a una clase de N-cianopirrolidinas con actividad como inhibidores de la enzima de desubiquitinación USP30, que tiene utilidad en una variedad de áreas terapéuticas, incluyendo condiciones que involucran la disfunción mitocondrial, cáncer y fibrosis: (ver Fórmulas).
MX2022015254A 2020-06-04 2021-06-03 N-cianopirrolidinas con actividad como inhibidores de peptidasa especifica de ubiquitina 30. MX2022015254A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB2008401.8A GB202008401D0 (en) 2020-06-04 2020-06-04 Novel compounds
GBGB2016689.8A GB202016689D0 (en) 2020-10-21 2020-10-21 Novel compounds
GBGB2101935.1A GB202101935D0 (en) 2021-02-11 2021-02-11 Novel compounds
PCT/EP2021/064897 WO2021245186A1 (en) 2020-06-04 2021-06-03 N-cyanopyrrolidines with activity as usp30 inhibitors

Publications (1)

Publication Number Publication Date
MX2022015254A true MX2022015254A (es) 2023-01-11

Family

ID=76421953

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015254A MX2022015254A (es) 2020-06-04 2021-06-03 N-cianopirrolidinas con actividad como inhibidores de peptidasa especifica de ubiquitina 30.

Country Status (13)

Country Link
US (1) US20230303547A1 (es)
EP (1) EP4161920A1 (es)
JP (1) JP7796047B2 (es)
KR (1) KR20230019198A (es)
CN (1) CN115698001A (es)
AU (1) AU2021285130A1 (es)
BR (1) BR112022019722A2 (es)
CA (1) CA3185654A1 (es)
CO (1) CO2022017112A2 (es)
IL (1) IL298710A (es)
MX (1) MX2022015254A (es)
WO (1) WO2021245186A1 (es)
ZA (1) ZA202213866B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024544660A (ja) 2021-12-01 2024-12-03 ミッション セラピューティクス リミティド Ｕｓｐ３０阻害剤としての活性を有する置換ｎ－シアノピロリジン
GB202408928D0 (en) 2024-06-21 2024-08-07 Mission Therapeutics Ltd Novel compounds
GB202411060D0 (en) 2024-07-29 2024-09-11 Mission Therapeutics Ltd Novel compounds
CN119528901A (zh) * 2024-11-05 2025-02-28 上海市同济医院 噻唑类化合物、去sumo和/或去泛素化酶抑制剂及其制备方法和应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2001077073A1 (en) 2000-04-06 2001-10-18 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
US20100022568A1 (en) 2006-04-13 2010-01-28 Actelion Pharmaceeuticals Ltd. Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
EP2152079A4 (en) 2007-06-04 2011-03-09 Avila Therapeutics Inc HETEROCYCLIC COMPOUNDS AND USES THEREOF
PE20090606A1 (es) 2007-08-20 2009-06-17 Glaxo Group Ltd Nuevos inhibidores de catepsina c y uso
AR071480A1 (es) 2008-04-18 2010-06-23 Glaxo Group Ltd Compuesto de 1- ciano -3- pirrolidinil -bencenosulfonamida composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar la enfermedad pulmonar obstructiva cronica (copd )
PE20091888A1 (es) 2008-04-18 2010-01-17 Glaxo Group Ltd Inhibidores de catepsina c
WO2009129370A1 (en) 2008-04-18 2009-10-22 Glaxo Group Limited Cathepsin c inhibitors
US20120309820A1 (en) 2011-06-04 2012-12-06 Jb Therapeutics Inc. Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids
EP2565186A1 (en) 2011-09-02 2013-03-06 Hybrigenics S.A. Selective and reversible inhibitors of ubiquitin specific protease 7
MX367085B (es) 2013-07-31 2019-08-05 Merck Patent Gmbh Piridinas, pirimidinas y pirazinas como inhibidores de tirosina cinasa de bruton e inhibidores y usos de las mismas.
EP3145505A4 (en) 2014-05-19 2018-02-28 Northeastern University N-acylethanolamine hydrolyzing acid amidase (naaa) inhibitors and their use thereof
EP3148572A4 (en) 2014-05-27 2017-12-27 Pharmakea, Inc. Compositions and methods of delivery of deubiquitinase inhibitors
WO2016019237A2 (en) 2014-07-31 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
GB201416754D0 (en) 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
MY188957A (en) * 2015-03-30 2022-01-14 Mission Therapeutics Ltd 1-cyano-pyrrolidine compounds as usp30 inhibitors
US10669234B2 (en) 2015-07-14 2020-06-02 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer
GB201521109D0 (en) 2015-11-30 2016-01-13 Mission Therapeutics Ltd Novel compounds
GB201522267D0 (en) 2015-12-17 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201522768D0 (en) 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201602854D0 (en) 2016-02-18 2016-04-06 Mission Therapeutics Ltd Novel compounds
GB201603779D0 (en) 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
GB201604638D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
GB201604647D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
WO2017163078A1 (en) 2016-03-24 2017-09-28 Mission Therapeutics Limited 1-cyano-pyrrolidine derivatives as dbu inhibitors
JP6959332B2 (ja) 2016-09-27 2021-11-02 ミッション セラピューティクス リミティド Ｕｓｐ３０の阻害剤としての活性を有するシアノピロリジン誘導体
GB201616511D0 (en) * 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
US10968172B2 (en) 2017-05-15 2021-04-06 Mitobridge, Inc. USP30 inhibitors
GB201708652D0 (en) 2017-05-31 2017-07-12 Mission Therapeutics Ltd Novel compounds and uses
GB2563595B (en) 2017-06-19 2020-04-15 Edwards Ltd Twin-shaft pumps
SG11202001684PA (en) 2017-10-06 2020-03-30 Forma Therapeutics Inc Inhibiting ubiquitin specific peptidase 30
GB2571731A (en) 2018-03-06 2019-09-11 Mission Therapeutics Ltd Novel compounds and uses
ES2988920T3 (es) 2018-05-17 2024-11-22 Forma Therapeutics Inc Compuestos bicíclicos fusionados útiles como inhibidores de la peptidasa 30 específica de ubiquitina
JP7434285B2 (ja) 2018-08-14 2024-02-20 アムジエン・インコーポレーテツド Ｎ－シアノ－７－アザノルボルナン誘導体及びその使用
PL3860989T3 (pl) 2018-10-05 2023-07-10 Forma Therapeutics, Inc. Sprzężone piroliny, które działają jako inhibitory proteazy 30 swoistej dla ubikwityny (usp30)
GB201905375D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201905371D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201912674D0 (en) 2019-09-04 2019-10-16 Mission Therapeutics Ltd Novel compounds

Also Published As

Publication number Publication date
CA3185654A1 (en) 2021-12-09
US20230303547A1 (en) 2023-09-28
EP4161920A1 (en) 2023-04-12
CN115698001A (zh) 2023-02-03
ZA202213866B (en) 2024-07-31
AU2021285130A1 (en) 2023-01-19
CO2022017112A2 (es) 2022-12-09
WO2021245186A1 (en) 2021-12-09
IL298710A (en) 2023-02-01
JP7796047B2 (ja) 2026-01-08
KR20230019198A (ko) 2023-02-07
JP2023529570A (ja) 2023-07-11
BR112022019722A2 (pt) 2022-12-20

Similar Documents

Publication Publication Date Title
ZA202203775B (en) Substituted cyanopyrrolidines with activity as usp30 inhibitors
ZA202212137B (en) N-cyanopyrrolidines with activity as usp30 inhibitors
ZA202213866B (en) N-cyanopyrrolidines with activity as usp30 inhibitors
CO2022017233A2 (es) 1-(5-(2-cianopiridin-4-il)oxazol-2-carbonil)-4-metilhexahidropirrolo[3,4-b]pirrol-5(1h)-carbonitrilo como inhibidor de usp30 para uso en el tratamiento de la disfunción mitocondrial, cáncer y fibrosis
MX2024014142A (es) Novedosos inhibidores de molecula peque?a de factores de transcripcion tead
MX379543B (es) Purinonas como inhibidores de proteasa específica de ubiquitina 1.
EA200801784A1 (ru) Ингибиторы е1 активирующих ферментов
UY27921A1 (es) Acidos tienil-hidroxamicos sustituidos y su uso para tratar enfermedades asociadas con la actividad enzimática de la histona desacetilasa
EA201592215A1 (ru) Антисмысловые олигомеры и их конъюгаты, направленные на пропротеин конвертазу субтилизин/кексин типа 9 (pcsk9)
MX2016006489A (es) Alfa-amilasas variantes que tienen susceptibilidad reducida a la escision por proteasas y metodos de uso.
PL1660507T5 (pl) Inhibitory proteazomu oraz sposoby ich stosowania
MX2022002946A (es) Inhibidores de cdk y su uso como productos farmaceuticos.
MX2022014429A (es) N-cianopirrolidinas con actividad como inhibidores de usp30.
EA202091205A1 (ru) Композиции для терапии гипергликемии и сопутствующих состояний
MX2023000164A (es) Métodos y composiciones para tratar la hemofilia.
EA200970284A1 (ru) Ингибиторы гистоновых дезацетилаз с сочетанной активностью в отношении гистоновых дезацетилаз класса i и класса ii в комбинации с ингибиторами протеасом
AR106538A1 (es) Métodos y composiciones para el tratamiento de la amiloidosis
MX2024006368A (es) Composiciones moduladoras de complemento del factor b y metodos de uso de estas.
MX2024011989A (es) Peptido que tiene actividades antiinflamatorias y antifibroticas y uso del mismo
MX2024012392A (es) Terapia combinada para el tratamiento del cancer
MX2023002416A (es) Compuestos, composiciones y metodos para la inhibicion de la desmetilasa de histona lisina.
MX2021014015A (es) Metodos basados en el genoma para reducir el riesgo cardiovascular.
ZA202210918B (en) Novel il10 agonists and methods of use thereof
WO2023019100A3 (en) Novel therapeutic methods of using peptidoglycan muropeptides to promote atp synthase activity and mitochondrial homeostasis and development
BR112023017235A2 (pt) Composições e métodos antivirais